Art. -Nr.: HY-111374

NMDI14

16 Cited Publications

Kundenbewertung

Based on 16 publication(s) in Google Scholar

NMDI14 is a nonsense mediated RNA decay (NMD) inhibitor. NMDI14 disrupts the SMG7-UPF1 interactions and inhibits NMD.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.68%
CAS. Nr.: 307519-88-6
Formel: C₂₁H₂₅N₃O₄S
Molecular Weight:415.51

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

NMDI14 Chemical Structure

CAS. Nr.: 307519-88-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
Chemical Information
Publications (16)
Lösungsmittel & Löslichkeit
- In Vitro
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

NMDI14 is a nonsense mediated RNA decay (NMD) inhibitor. NMDI14 disrupts the SMG7-UPF1 interactions and inhibits NMD.

IC₅₀ & Target

NMD^[1]

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

In Vitro

NMDI14 is a nonsense mediated RNA decay (NMD) inhibitor. Treating cells with NMDI14 for 6 hours leads to an increase of PTC 39 β globin to 12%, a relative four-fold increase that, if resulting in biologically active hemoglobin, would be sufficient to ameliorate the clinical symptoms of thalassemia. Three days of treatment with NMDI14 results in no decrease in cell counts, demonstrating that the pharmacological inhibition of NMD can be achieved without subtle changes in proliferation. 941 genes are increased >1.5 fold with NMDI14. The treatment of N417 cells with NMDI14 for 6 hours leads to a steady state expression of p53 similar to that seen in U2OS cells. NMDI14 significantly increases the stability of PTC mutated p53 mRNA in N417 cells, without altering the stability of wild-type p53 in NMDI-treated U2OS cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS. Nr. 307519-88-6
Appearance Solid
Molecular Weight 415.51
Formel C₂₁H₂₅N₃O₄S
Color Light yellow to yellow
SMILES

O=C(C1=C(NC(CC2NC3=C(C=C(C)C(C)=C3)NC2=O)=O)SC(C)=C1C)OCC
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (16)

All RT-PCRWB

Sort by:

Journal Impact Factor

Nature

Engineered tRNAs suppress nonsense mutations in cells and in vivo. [Abstract]

2023 Jun;618(7966):842-848. PMID: 37258671

NMDI14 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7966):842-848. [Abstract]

NMDI14 (NMD14; 5 µM; 12 h). CFTR mRNA level was normalized to that in untreated cells.

NMDI14 purchased from MedChemExpress. Usage Cited in: Nature. 2023 Jun;618(7966):842-848. [Abstract]

NMDI14 (NMD14; 5 µM; 24 h). Representative immunoblots using monoclonal CFTR-NBD2 antibody in 16HBEge^R1162X/− transfected with sup-tRNA alone using lipofectamine or treated with NMD14.
Nat Commun

A UFD1 variant encoding a microprotein modulates UFD1f and IPMK ubiquitination to play pivotal roles in anti-stress responses. [Abstract]

2025 Jul 21;16(1):6695. PMID: 40691175

NMDI14 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 21;16(1):6695. [Abstract]

NMDI14 (50 μM; 6 h). RT-qPCR analysis revealing lncRNA GAS5 and UFD1s RNA levels in HEK293T cells under NMDI14 or TG treatments. GAS5 is a known NMD target, and was served as a positive control.
Adv Sci (Weinh)

ADAR1-HNRNPL-Mediated CircCANX Decline Promotes Autophagy in Chronic Obstructive Pulmonary Disease. [Abstract]

2025 May;12(18):e2414211. PMID: 40091520

NMDI14 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 May;12(18):e2414211. [Abstract]

NMDI14 (5-10 μM; 48 h). P53 expression in cells overexpressing circCANX or its control and treated with NMDI14 based on western blotting.
Cell Rep Med

Recreating pathophysiology of CLN2 disease and demonstrating reversion by TPP1 gene therapy in hiPSC-derived retinal organoids and retina-on-chip. [Abstract]

2025 Aug 19;6(8):102244. PMID: 40706588
Diabetologia

A WFS1 variant disrupting acceptor splice site uncovers the impact of alternative splicing on beta cell apoptosis in a patient with Wolfram syndrome. [Abstract]

2025 Jan;68(1):128-151. PMID: 39520565

NMDI14 purchased from MedChemExpress. Usage Cited in: Diabetologia. 2025 Jan;68(1):128-151. [Abstract]

NMDI14 (5 μM; 16 h). RT-qPCR of the four WFS1 isoforms in WFS1 iPSCs after treatment with NMDI-14 or vehicle.
Anesthesiology

Phosphorylated upstream frameshift 1-dependent nonsense-mediated μ opioid receptor mRNA decay in the spinal cord contributes to the development of neuropathic allodynia-like behavior in rats. [Abstract]

2023 Jun 1;138(6):634-655. PMID: 36867667
Oncogene

KPNA2 promotes osteosarcoma progression by regulating the alternative splicing of DDX3X mediated by YBX1. [Abstract]

2025 Jul;44(26):2186-2200. PMID: 40216969
Cell Rep

Vascular Lamb1 guides the migration of retinal microglial precursors via Itga6-Rac1 signaling. [Abstract]

2025 Nov 25;44(11):116544. PMID: 41206867
Cell Rep

Inhibiting UPF1 methylation enhances tumor immunotherapy sensitivity by reducing nonsense-mediated mRNA decay. [Abstract]

2025 Jun 25;44(7):115919. PMID: 40570371
Neurosci Bull

A Novel Mouse Model Unveils Protein Deficiency in Truncated CDKL5 Mutations. [Abstract]

2025 May;41(5):805-820. PMID: 40042769
Cell Signal

Two novel SH3TC2 mutations predispose to Charcot-Marie-Tooth disease type 4C by mistargeting away from TFRC. [Abstract]

2025 Jun:130:111669. PMID: 39961410
Eur J Immunol

Interferons and Cytokines Induce Transcriptional Activation of the Long-Interspersed Element-1 in Myeloid Cells from Autoimmune Patients. [Abstract]

2025 Mar;55(3):e2451351. PMID: 40071709
eNeuro

Fine-tuning amyloid precursor protein expression through non-sense mediated mRNA decay. [Abstract]

2024 May 24:ENEURO.0034-24.2024. PMID: 38789273
SSRN

2025 Nov 21.
Genet Med Open

CFTR rescue in W1282X cystic fibrosis patient-derived intestinal organoids (PDIOs) mediated by translational readthrough-inducing drugs (TRIDs). [Abstract]

2025 Nov 17:4:103472. PMID: 41492359
bioRxiv

2025 Oct 15.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 10 mg/mL (24.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4067 mL

12.0334 mL

24.0668 mL

5 mM

0.4813 mL

2.4067 mL

4.8134 mL

10 mM

0.2407 mL

1.2033 mL

2.4067 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Protokoll

Cell Assay^[1]

To assess viability cells are cultured in 6 well dishes and incubated with DMSO, G418, NMDI alone or G418 with NMDI together for the indicated hours. After incubations, cells and media are collected and cells viability is measured. To assess cell proliferation U2OS, Hela and BJ-htert cells are cultured in 6 well plates and, after 24 hrs, treated with NMDI14 for 0, 24, 48 and 72hrs. The cells are collected and viable cells are counted by using the Countess Automated Cell Counter^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Martin L, et al. Identification and characterization of small molecules that inhibit nonsense-mediated RNA decay and suppress nonsense p53 mutations. Cancer Res. 2014 Jun 1;74(11):3104-1 [Content Brief]

[2]. Aksit MA, Bowling AD, Evans TA, et al. Decreased mRNA and protein stability of W1282X limits response to modulator therapy. J Cyst Fibros. 2019;18(5):606-613. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4067 mL	12.0334 mL	24.0668 mL	60.1670 mL
	5 mM	0.4813 mL	2.4067 mL	4.8134 mL	12.0334 mL
	10 mM	0.2407 mL	1.2033 mL	2.4067 mL	6.0167 mL
	15 mM	0.1604 mL	0.8022 mL	1.6045 mL	4.0111 mL
	20 mM	0.1203 mL	0.6017 mL	1.2033 mL	3.0084 mL

Keywords

NMDI14

16 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

NMDI14

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) NMDI14

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (16)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NMDI14

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Heterocyclic Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) NMDI14

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (16)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

NMDI14 Related Classifications

HY-111374 Related Classifications